Teva beats, signs license agreements, ups outlook

 

Teva beats Q3 estimates and issues initial 2027 outlook targeting gross margin roughly 57%-58% and operating margin expansion of 180-220 bps from 2026 levels

• Q3 non-GAAP EPS $0.86, +10% YoY, on revenue $4.4B, -2% YoY, both beating estimates.
• Initial 2027 margin outlook was provided during Teva's Q3 earnings call.
• Teva raised 2026 outlook for AUSTEDO, AJOVY, UZEDY and non-GAAP operating income following Q3 results.
• 2026 UZEDY revenue outlook increased to $290M–$310M from prior $270M–$290M range.
• UZEDY U.S. net sales were reported at $85M in Q3 2026.
• Teva signs U.S. license and commercialization deal with Samsung Bioepis for FDA-approved immunology biosimilars ETICOVO and infliximab-abda.
• Agreement includes U.S. profit-sharing structure with upfront and milestone payments between Teva and Samsung Bioepis.

https://finviz.com/stock?t=TEVA&p=d